Author:
Pan Dengyun,Wang Qi,Yan Bingdi,Su Xiaomin
Funder
“13th five-year plan” Science and Technology Research Project of Jilin Provincial Department of Education
the Youth Science and Technology Backbone Training Program of Health Commission of Jilin Province
the Medical and Health Talent Special Project of Jilin Province - National Natural Science Foundation of China Cultivation Project
National Natural Science Foundation of China
Norman Bethune Program of Jilin University
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Glassberg MK. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. Am J Manag Care. 2019;25(11 Suppl):S195–203.
2. Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021;222:107798.
3. Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2022;17:515–46.
4. Mortimer KM, Bartels DB, Hartmann N, Capapey J, Yang J, Gately R, et al. Characterizing health outcomes in idiopathic pulmonary fibrosis using US health claims data. Respiration. 2020;99(2):108–18.
5. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Resp Res. 2021;22(1):197.